Assessment of XXXX aglycones variability in soy food supplements using a validated HPLC-UV method.

@entity8139 @entity6400 @entity670 @entity3093 @entity1009 @entity1626 @entity8136 @entity1543
BACKGROUND AND AIMS: Soy supplements are often recommended in the management of menopause symptoms. The declared content of soy supplements is commonly expressed as total @entity6400 per dosage form. Given that soy @entity6400 have different estrogenic potencies, pharmacokinetics and metabolism, the aim of this study was to evaluate the total @entity3093 content and the aglycone profile of seven soy supplements and one soy seed extract. Label accuracy was assessed, in relation to the precise content and the recommended posology for estimating whether the optimal dose is achieved for alleviating menopause symptoms. METHODS: A high performance liquid chromatography method was developed for evaluating the aglycone content ( @entity670 , @entity8139 , @entity8136 ). After extraction and acidic hydrolysis, the aglycones were separated on a C18 column, using 0.1% @entity1543 and @entity1626 as mobile phases. The flow rate was 1.5mL @entity1009 ) and the UV detector wavelength was set at 260nm. A linear relationship was found in the range 5-80 g mL(-1). The method was validated using the accuracy profile methodology. RESULTS: The total @entity3093 content ranged from 6.07 to 41.68mg dosage form(-1). Various aglycone profiles were obtained for each supplement which can result in a different estrogenic activity, bioavailability and finally, in a different efficiency in alleviating menopause symptoms. In most clinical trials where soy @entity6400 were evaluated, little attention was paid to determining the exact aglycone profile of the employed soy extracts. CONCLUSIONS: As clinical outcomes continue to be controversial, this study highlights the need of standardization in @entity670 , rather than total @entity6400 and labeling accuracy for soy supplements.
